Cable Hill Partners LLC Decreases Stock Holdings in Novartis AG (NYSE:NVS)

Cable Hill Partners LLC reduced its holdings in Novartis AG (NYSE:NVS) by 31.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,185 shares of the company’s stock after selling 3,748 shares during the period. Cable Hill Partners LLC’s holdings in Novartis were worth $796,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Centaurus Financial Inc. raised its stake in shares of Novartis by 1.7% during the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after acquiring an additional 98 shares in the last quarter. Allen Wealth Management LLC grew its holdings in Novartis by 1.8% in the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after purchasing an additional 100 shares during the last quarter. WealthPlan Investment Management LLC increased its position in shares of Novartis by 1.1% during the third quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company’s stock worth $1,092,000 after purchasing an additional 100 shares in the last quarter. Bryn Mawr Capital Management LLC lifted its holdings in shares of Novartis by 0.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock valued at $1,254,000 after purchasing an additional 100 shares during the last quarter. Finally, Rothschild Investment LLC boosted its position in shares of Novartis by 0.6% in the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock worth $1,623,000 after purchasing an additional 101 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Barclays restated an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets lifted their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Stock Performance

NVS opened at $107.95 on Thursday. The firm has a 50 day moving average of $102.12 and a two-hundred day moving average of $108.08. The firm has a market capitalization of $220.64 billion, a PE ratio of 18.36, a P/E/G ratio of 1.70 and a beta of 0.58. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92.

Novartis (NYSE:NVS) last posted its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, analysts anticipate that Novartis AG will post 8.45 EPS for the current year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.